Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02612623 · ClinicalTrials.gov registry record · Phase 2
An 8-Week Refractory Chronic Cough Study (MK-7264-021)
A Phase 2 study, sponsored by Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT02612623: Completed Phase 2 study, sponsored by Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
NCT02612623 is a Phase 2 study that has completed, run by Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02612623, a Phase 2 study, has completed, sponsored by Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
This was an 8-week randomized, parallel, double-blind, placebo-controlled study of gefapixant (AF-219) in participants with refractory chronic cough.
Interventions
- DRUG Gefapixant
- DRUG Placebo (for gefapixant)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-12-17 |
| Est. Completion | 2016-05-18 |
| Phase | Phase 2 |
Sponsor
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)6 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02612623
The ClinicalTrials.gov registry entry for NCT02612623 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gefapixant is the first listed.
NCT02612623 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02612623 about?
NCT02612623 is a clinical study titled "An 8-Week Refractory Chronic Cough Study (MK-7264-021)". This was an 8-week randomized, parallel, double-blind, placebo-controlled study of gefapixant (AF-219) in participants with refractory chronic cough.
What is the current status of trial NCT02612623?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2015-12-17. Estimated completion is 2016-05-18.
What interventions are being tested in trial NCT02612623?
The interventions under investigation include: Gefapixant (DRUG), Placebo (for gefapixant) (DRUG).
Who is sponsoring clinical trial NCT02612623?
This trial is sponsored by Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.